Biocon India Case Study

Biogen Idec displayed strong operational, commercial and financial performance in 2006. However, new market opportunities and the challenges of the next decade have led the

India has become a global conduit for business as they have liberalized their economic policies over the past 20 years. Companies are flocking to India because of many factors, including, less expensive labor costs, increasing growth rate, and an abundance of a highly skilled workforce. These factors in addition to other advantages have substantially increased the number of United States businesses looking to grow beyond the U. S borders into the county of India. Dunlop Software Consultant’s goal is to also expand its operations internationally and believes that India has the business environment to meet our goal of expansion globally.

Davies P. (2004). What's This India Business?: Offshoring, Outsourcing, and the Global Services Revolution. London: Nicholas Brealey International.

Outsourcing is a method used by many corporations in which their products are manufactured in foreign countries often for cheaper labor.This method method of productions has it’s pros and cons.

Every organization has the opportunity to maximize their return by how they strategically fit themselves in their respective market place and by how they manage the internal assets to maximize their utilization. InVentiv Health is a Contract Research Organization (CRO) that provides support for commercialization, preclinical research, clinical research and clinical trials management within the pharmaceutical industry. InVentiv Health specializes in clinical trial services and offers their clients the expertise of moving an asset, drug or device through the FDA approval process, from conception to

In 1998, Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes”. Biopure has invested $200M on the R&D on blood substitutes in the past with its primary goal being the development of a human blood substitute ( Hemopure) but Its entry into animal market (Oxyglobin) had been some

Instead of collecting income only during the day time like it has been for the past 15 years, outsourcing to India will allow our company to be working 24/7 due to the time zones.

The issues presented in business aspects of clinical laboratories are agreeable as valid challenges for commercial investors. I do believe that the most important issue presented in the content is marketing challenges for commercialized testing.

First Ms. Hills let me congratulate you for being appointed to the board of directors, I’m looking forward to work with you. Mylan is poised for growth even though it faced a difficult situation with the EpiPen pricing earlier in the year. The imminent release of a generic version of the EpiPen will get Mylan back on track to “Doing what’s right, not what’s easy”. Adding to that, the acquisition of MEDA gave Mylan a more diversified portfolio with $2.3 billion in annual revenue. Also, the partnership with Biocon will get Mylan into a $33 Billion market by 2023. With the combination of this three issues Mylan is on the right track to get closer to the mission of providing 7 billion people access to high quality medicine.

The key issue is to determine when Oxyglobin should be introduced to the market without jeopardizing Hemopure’s potential and how it should be marketed.

The meteoric rise of India in the area of IT and Business Process Outsourcing (BPO) was attributed to resource and industry based view of IB strategy (Peng et al 2008). These views are based on the opinion that cheap labour, excellent skills and virtuality are major factors responsible for their growth. Nonetheless, institutional considerations are found to be quite relevant in India’s context. Considerations in the areas of education subsidy to top Universities and various economic reforms including liberalisation by government institutions played crucial roles in making India a competitive environment for investments (Peng et al 2008). These institutional references can conveniently stand as the third tripod of the IB strategy.

Achieve a median composite eight-year product development cycle by 2010. Deliver two new molecular entity (NME) launches on average per year from 2010. In order to achieve the above objective, ensure that we have 10 or more NMEs in Phase III development by 2010. Development cycle times and quality for small molecules and biologics. Number of NME launches per year. Attrition rates. Number of development projects by phase. Number of in-licensing deals, alliances and acquisitions. R&D investment levels. Improving R&D quality and speed through leading-edge science, effective risk management and decision-making and overall business efficiency. Maximising the value of our biologics business and continuing to build a major presence in this fast-growing sector. Investing in external opportunities to enhance our internal innovation through in-licensing, alliances and acquisitions. 2008 target exceeded for small molecule development cycle times. NME and life-cycle management progressions

In practice, experts agree that there are relatively fewer computer network and identity theft breaches in India than in the United States. All the same, this underscores the importance of working with a reputable and experienced firm if outsourcing processes to India.

Dash, S. & Agarwal, R. (2005). Determining India’s Edge in IT Outsourcing: A Cross Country Analysis of Comparative Advantage in IT, in Upadhay V.ed. et.al (2005) Productivity and Quality Research, Tata Mcgraw Hill, New Delhi.

Alternative 3 is the chosen alternative course action since it has more Pros than Cons and could arise with more benefits than Risks. › Proper segregation of duties and Management assignment for monitoring the outsourced goods and further background check on ATF › Assignment of personnel in charge of the monetary reserves to be incurred as the result of outsourcing, it should ne notified that there saved money shall be use for the mining and agricultural pumps development ›